H.C. Wainwright keeps Buy rating on Acceleron after updated luspatercept timing.

After Acceleron’s (XLRN) partner, Celgene (CELG), announced updated timing for the anticipated submission of a Biologics License Application with the U.S. FDA for luspatercept, H.C. Wainwright analyst Edward White noted that the BLA is now seen being submitted in April 2019, versus prior guidance for the first half of 2019. He expects the drug to be launched in early 2020 and his expectations remain at $32.5M in 2020 sales for beta-thalassemia and $131.3M in 2020 sales for myelodysplastic syndromes, or MDS. White keeps a Buy rating and $72 price target on Acceleron shares.
https://thefly.com/landingPageNews.php?id=2870447